PA
DNLI icon

Perceptive Advisors’s Denali Therapeutics DNLI Stock Holding History

Perceptive Advisors’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-850,000
Closed -$14.9M – 129
2020
Q1 		$14.9M Buy
+850,000
New +$17.7M 0.39% 49

Other funds holding DNLI

CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Perceptive Advisors's DNLI Position: Q2 2020 in Review

Perceptive Advisors sold out of Denali Therapeutics (DNLI) in Q2 2020, closing a stake of 850,000 shares — an estimated $14.9M sold.

Perceptive Advisors first reported a position in DNLI in Q1 2020 and held it in 1 quarter. The position peaked at $14.9M in Q1 2020. 148 funds tracked by Wall St. Rank hold DNLI as of Q2 2020.

  • Perceptive Advisors reported no remaining Denali Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Perceptive Advisors sold 850,000 Denali Therapeutics shares in Q2 2020, an estimated $14.9M.
  • Perceptive Advisors first reported a position in Denali Therapeutics in Q1 2020 and held it in 1 quarter.
  • Perceptive Advisors's Denali Therapeutics position peaked at $14.9M in Q1 2020.
  • 148 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2020.

Based on Perceptive Advisors's 13F filing for Q2 2020, filed 14 Aug 2020.